India’s first intranasal vaccine for Covid gets DCGI approval
India's first intranasal Covid vaccine by Bharat Biotech on Tuesday got the approval from the Drug Controller General of India for 18+ age group for restricted use in emergency situation.
India's first intranasal Covid vaccine by Bharat Biotech on Tuesday got the approval from the Drug Controller General of India for 18+ age group for restricted use in emergency situation.
DCGI Official said that the “Made in India” drugs will have an important effect and hit the world differently in upcoming years.
The statement further said that Covovax is the fourth vaccine to receive EUA from the DCGI for use among adolescents 12 and older.
The clinical trials will be conducted at nine different sites, including AIIMS Delhi.
Sun Pharma, in a statement, said that under the brand name Molxvir, they would launch Molnupiravir within a week.
Earlier in July, the Subject Expert Committee of the Central Drugs Standard Control Organisation (CDSCO) had refused to grant emergency-use authorisation to Sputnik-Light.
The trial aims to prevent symptomatic Covid-19 infections, as well as reduce severe disease and asymptomatic infection.
People for the Ethical Treatment of Animals (PETA) India, on Thursday, requested the Drugs Controller General of India (DCGI) to…
The committee after detailed deliberation recommended for grant of permission to conduct the proposed Phase II-III clinical trial to certain conditions.
For the development of Virafin, Zydus appreciated the support provided by DBT-BIRAC COVID 19 Research Consortium through NBM, for conducting the Phase II human clinical trial studies.
